TPWA
MDGL icon

Twin Peaks Wealth Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.71K Buy
+9
New +$4.3K ﹤0.01% 1417
2025
Q3 		– Sell
-5
Closed -$1.79K – 1321
2025
Q2 		$1.79K Buy
+5
New +$1.49K ﹤0.01% 1652

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Twin Peaks Wealth Advisors's MDGL Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Madrigal Pharmaceuticals (MDGL) in Q1 2026: 9 shares worth $4.71K. The stake represents ﹤0.01% of the portfolio and ranks #1417 among its holdings. This is a return to the name: Twin Peaks Wealth Advisors previously reported a position in MDGL as recently as Q2 2025.

Twin Peaks Wealth Advisors first reported a position in MDGL in Q2 2025 and has held it in 2 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Twin Peaks Wealth Advisors held 9 shares of Madrigal Pharmaceuticals worth $4.71K as of Q1 2026.
  • Madrigal Pharmaceuticals was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #1417 holding.
  • Twin Peaks Wealth Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.